Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sensus Healthcare to Participate in Two Upcoming Investor Conferences on November 30th and December 1st

SRTS

-- Evercore ISI MedTools Investor Conference in Boston, MA

-- Drexel Hamilton's Emerging Growth Conference in New York, NY

PR Newswire

BOCA RATON, Fla., Nov. 16, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in two upcoming investor conferences:

  • Evercore ISI MedTools Investor Conference to be held at the Boston Harbor Hotel in Boston, MA on Wednesday, November 30, 2016.
  • Drexel Hamilton's Emerging Growth Conference to be held at the Drexel Hamilton Offices, 77 Water Street in New York, NY on Thursday, December 1, 2016. Joe Sardano will present at 1:30pm ET. The presentation will be available via live audio webcast and archived replay on Sensus' investor relations website at investors.sensushealthcare.com/events-and-presentations.

Investors attending the conferences who wish to meet with management for a one-on-one meeting should notify their appropriate contact.

For more information and registration, please visit the conference websites: Evercore ISI and Drexel Hamilton.

About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-two-upcoming-investor-conferences-on-november-30th-and-december-1st-300363952.html

SOURCE Sensus Healthcare

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today